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Abstract
Background: Studies have described vasculogenic mimicry (VM) as an alternative circulatory system to blood
vessels in multiple malignant tumor types, including hepatocellular carcinoma (HCC). In the current study, we
aimed to seek novel and more efficient treatment strategies by targeting VM and explore the underlying
mechanisms in HCC cells.
Methods: Cell counting kit-8 (CCK-8) assay and colony survival assay were performed to explore the inhibitory
effect of incarvine C (IVC) on human cancer cell proliferation. Flow cytometry was performed to analyze the cell
cycle distribution after DNA staining and cell apoptosis by the Annexin V-PE and 7-AAD assay. The effect of IVC on
Rho-associated, coiled-coil-containing protein kinase (ROCK) was determined by western blotting and stress fiber
formation assay. The inhibitory role of IVC on MHCC97H cell VM formation was determined by formation of tubular
network structures on Matrigel in vitro, real time-qPCR, confocal microscopy and western blotting techniques.
Results: We explored an anti-metastatic HCC agent, IVC, derived from traditional Chinese medicinal herbs, and
found that IVC dose-dependently inhibited the growth of MHCC97H cells. IVC induced MHCC97H cell cycle arrest at
G1 transition, which was associated with cyclin-dependent kinase 2 (CDK-2)/cyclin-E1 degradation and p21/p53
up-regulation. In addition, IVC induced apoptotic death of MHCC97H cells. Furthermore, IVC strongly suppressed
the phosphorylation of the ROCK substrate myosin phosphatase target subunit-1 (MYPT-1) and ROCK-mediated
actin fiber formation. Finally, IVC inhibited cell-dominant tube formation in vitro, which was accompanied with the
down-regulation of VM-key factors as detected by real time-qPCR and immunofluorescence.
Conclusions: Taken together, the effective inhibitory effect of IVC on MHCC97H cell proliferation and neovascularization
was associated with ROCK inhibition, suggesting that IVC may be a new potential drug candidate for the
treatment of HCC.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon malignancy and the third most common cause of
cancer-related deaths [1]. Uncontrolled tumor growth,
metastasis and the absence of effective therapeutics ac-
count for the poor overall survival (OS) of HCC patients.
Although surgical resection improves survival, the prog-
nosis for HCC remains unsatisfactory, mainly because of
intrahepatic dissemination and extrahepatic metastasis [2].
Angiogenesis is required for metastasis [3, 4], and several
mechanisms of tumor vessel formation have been pro-
posed, including vasculogenesis, angiogenesis, intussus-
ceptions, vascular cooption and vasculogenic mimicry
(VM). VM describes the de novo formation of perfusable,
matrix-rich and vasculogenic-like networks by aggressive
tumor cells in 3-dimensional (3D) matrices in vitro, which
parallels matrix-rich networks in aggressive tumors in
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patients [5]. Studies have described VM as an alternative
circulatory system to blood vessels in multiple malignant
tumor types, including HCC [6].
VM, which recapitulates embryonic vasculogenesis [7],
was reported to be associated with high tumor grade,
short survival, and invasion and metastasis in clinical
trials [8–10]. The initial morphologic and molecular
characterization of tumor VM cells revealed co-expression
of endothelial and tumor markers and formation of func-
tional tubular structures containing plasma and red blood
cells, indicating a perfusion pathway for rapidly growing
tumors [11]. In addition, the direct exposure of tumor
cells lining the inner surface of VM channels to blood flow
indicates an escape route for the metastasis process.
Considering the diverse nature of vascular perfusion
pathways in tumors, it may be prudent to test the effi-
cacy of currently available angiogenesis inhibitors on
tumor cell VM in addition to angiogenesis driven by
endothelial cells [12].
Rho small GTPase and its serine/threonine kinase
downstream effector ROCK play a crucial role in diverse
cellular events, including the acquisition of unlimited
proliferation potential, survival and evasion from apop-
tosis, tissue invasion differentiation, gene expression,
regulation of cell detachment, cell movement and estab-
lishment of metastasis [13, 14]. Recently, growing atten-
tion has been paid to the emerging role of the
cytoskeleton in the modulation of cell cycle and apop-
tosis. In some cell types, ROCK is involved in the intra-
cellular signaling that initiates apoptosis, such as
Caspase8, Caspase10, and Caspase3 activation [15], or
the transcription of proapoptotic proteins, such as Bax
[16]. Interestingly, our previous study showed that
ROCK was involved in VM formation in an HCC cell
line [17], and we hypothesized that unlimited prolifera-
tion triggered by ROCK activation may be the key point
of regulating tumor cell VM and endothelial cell-driven
angiogenesis simultaneously.
Incarvine C (IVC), an ester alkaloid isolated from the
traditional Chinese medicinal plant Incarvillea sinensis
(Bignoniaceae), also known as “Jiaohao (Kakko)” or
“Tougucao” [18], has long been used for treating rheuma-
tism and relieving pain in traditional Chinese medicine.
However, most alkaloids, originally identified as having
anti-inflammatory and anti-viral activities, now are also
known to have anti-tumor activities by targeting the apop-
tosis pathways in cancer [19]. IVC, originally identified as
a precursor compound of incarvillateine, has similar activ-
ities to morphine [20]. However, the potential effect of
IVC on VM and proliferation of highly metastatic HCC
cells through ROCK has not been fully studied.
In the current study, with the aim of developing novel
and more efficient treatment strategies by targeting VM,
we explored the underlying mechanisms of IVC on VM
in HCC cells. Our results showed that IVC had a pro-
found inhibitory effect against MHCC97H cell prolifera-
tion and migration by promoting MHCC97H cell cycle
arrest and apoptotic death. Our findings may serve as
strong evidence to suggest that IVC executes a significant
inhibitory effect against VM and migration of MHCC97H
cells by regulating ROCK, and therefore IVC may prove
to be a promising anti-HCC agent.
Methods
Chemical and antibodies
Chemicals and antibodies used in this study include Matri-
gel (BD Biosciences); cell culture media (RPMI 1640,
DMEM and MEM), fetal bovine serum (FBS) and antibi-
otics (Gibco); Y27632 and other chemicals (Sigma-Aldrich);
anti-VE-cadherin, MYPT-1 and p-MYPT-1(Thr853) anti-
bodies (Cell Signaling); PE Annexin V Apoptosis Detection
Kit and PI/RNase Staining Buffer (BD PharmingenTM).
The other reagents were purchased from Abcam Inc.
(Cambridge).
IVC preparation
IVC was extracted as previously described with some
modifications [18]. The air-dried powered aerial part
(15 kg) of I. sinensis was refluxed with 80 % EtOH
(30 L). The aq. brownish syrup (6 L) obtained after re-
moving EtOH under reduced pressure was dissolved in
2 % HCl solution and filtered. The filtrate was adjusted
to pH 9–10, mixed with NH4OH, and extracted with
CHCl3. The CHCl3 extract (68 g) was subjected to col-
umn chromatography on silica gel (SiO2, 200–300 mesh)
with a petroleum ether/AcOEt gradient elution system
(100:1→ 5:1) to yield five fractions (1–5). Fraction 5 was
purified repeatedly by eluting with CHCl3/MeOH (1:2)
to afford IVC (6 mg). The IVC solution at a concentra-
tion of 20 mg/ml was prepared by dissolving in dimethyl
sulfoxide (DMSO). The final DMSO concentration did
not exceed 0.5 % throughout the study.
Cell lines
The HCC cell line MHCC97H was obtained from the
Liver Cancer Institute, Zhongshan Hospital of Fudan
University (Shanghai, China). HCC cell lines SMMC7703,
SMMC7721, HepG2 and Hep3B; prostate carcinoma cells
PC3 and LNCap; lung cancer A549 cells; colon cancer
HCT116 cells; and cervical cancer Hela cells were from
the cell bank of the Chinese Academy of Sciences
(Shanghai, China). All cell lines were cultured separ-
ately in RPMI 1640 (HUVECs, SMMC7703, SMMC7721,
PC3, LNCap, A549), MEM (HepG2 and Hep3B) and
DMEM (MHCC97H, HCT116 and Hela), supple-
mented with 10 % FBS and antibiotics. All cultures
were maintained at 37 °C in a humidified atmos-
phere of 5 % CO2.
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Matrigel tube formation assay
Tumor cell formation of the capillary structure in vitro
was tested as previously described [17], except that the
effect of IVC on tube formation was studied by adding
culture medium containing IVC into the wells immedi-
ately after cell seeding to a final concentration of 7.5, 15
or 30 μM for 24 h.
Colony formation assay
MHCC97H cells treated with IVC for 48 h were har-
vested. A total of 1 × 103 cells per well suspended in
150 μl Mix agar with 1.5 ml DMEM/10 % FBS were
plated in a 6-well plate overlying a 1 % agar-DMEM/
10 % FBS (1:1) bottom layer. After 3 weeks, colonies
were photographed at 4×. The remaining survival large
colonies were manually counted.
Western blot analysis
Cells were treated with different concentrations of IVC or
Y27632 for 24 h. Total protein was extracted and elec-
trophoresed using SDS-PAGE. Proteins on the gel were
transferred onto PVDF membranes (Merck-Millipore),
followed by blocking with 5 % skimmed milk dissolved in
TBS containing 1 % Tween-20 (TBST) for 1 h at room
temperature. The membrane was incubated with primary
antibody at 4 °C overnight, washed with 1 % TBST three
times, and incubated with alkaline phosphatase-conjugated
secondary antibody for 1 h at room temperature. After
washing, the chemiluminescence signal was imaged using
ChemiDoc XRS (Bio-Rad) and quantitated using Image J.
cDNA generation and real-time qPCR
Cells were treated with 7.5, 15, 30 or 60 μM IVC for
16 h. Total RNA was extracted from cells using Trizol
(Invitrogen) and verified by electrophoresis. The mRNA
was reverse transcribed into cDNA with a reverse
transcription kit (Thermo Fisher Scientific). Human
GAPDH Endogenous Reference Genes Primers (Order
NO.: PHS04) and primer sequences listed in Tables 1
and 2 used for PCR were from Sangon Biotech. SYBR
Green I (Amersco) was added into the reaction mixture.
Real-time qPCR was performed on an MJ Opticon 2
thermal cycler (MJ Research Inc.) following the manu-
facturer’s instruction.
Immunostaining
After fixation for 20 min in 4 % paraformaldehyde at
37 °C, cells were permeabilized for 15 min in 0.5 %
Triton-X and subsequently blocked in 5 % goat serum
for 1 h. After incubation with the appropriate primary
(overnight incubation at 4 °C) and secondary (2 h at 37 °C)
antibodies, the cells were imaged using a confocal laser
scanning microscope (Leica TCS SP8).
Cell morphology assay
MHCC97H cells were plated at 8 × 103 cells per well in an
8-chamber slide in serum-free medium (serum starvation)
for 24 h. After serum starvation, cells were treated with
vehicle, Y27632 or IVC for 1 h. After treatment, cells were
fixed with 4 % paraformaldehyde, permeabilized using
0.1 % Triton X-100 and stained with phalloidin (Sigma,
USA) and DAPI (blue). Cells were imaged using a con-
focal laser scanning microscope (Leica TCS SP8).
Cell migration assay
Cell migration was evaluated using an in vitro wound
healing assay. In brief, MHCC97H cells containing IVC
at a final concentration of 7.5, 15 or 30 μM were seeded
to a six-well plate and incubated for 8 h to allow the for-
mation of a cell monolayer. Cells were scratched with
the tip of a 200 μl pipette and then incubated at 37 °C in
a humidified atmosphere of 5 % CO2 for 48 h. To ob-
serve the wound healing, each well was observed at 0,
24 and 48 h after scratching.
Matrigel invasion assay
Invasion was assayed in Transwell cell culture chambers
(Corning Costar) attached with a membrane filter
(8.0 μm pore size; Nucleopore). Briefly, the inserts in the
membrane filter were coated with Matrigel on the upper
surface. MHCC97H cells were adjusted to a density of
1 × 106 cells/ml in serum-free DMEM high glucose cul-
ture medium. Cell suspension (200 μl) was seeded into
the upper surface, while the lower chambers were filled
with 500 μl DMEM medium with 20 % FBS. After cul-
ture at 37 °C in a humidified atmosphere of 5 % CO2 for
48 h, the cells that invaded the Matrigel matrix and ad-
hered to the bottom surface of the membrane were fixed
with methanol and stained with 0.5 % crystal violet. The
number of invading cells was counted using an inverted
light microscope (Nikon, Japan). Assays were performed
in duplicate wells.
Cell apoptosis, cell cycle and cell viability assessment
Apoptosis and cell cycle of MHCC97H cells exposed to
IVC (3.75, 7.5, 15, 30 or 60 μM) for 24 h were examined
by flow cytometry (BD Accuri C6). For the apoptosis
assay, cells were stained with PE Annexin V and 7-
amino-actinomycin (7-AAD) following the manufac-
turer’s instructions to detect early apoptotic cells (PE
Annexin V+/7-AAD- events) and late apoptotic cells (PE
Annexin V+/7-AAD+ events). For the cell cycle assay,
cells were fixed with 70 % ethanol overnight at 4 °C,
washed with PBS, re-suspended in 500 μl PBS with
100 μg/ml RNase and incubated for 30 min at 37 °C.
Next, 2.5 μl PI solution (10 mg/ml) was added and cell
cycle was analyzed. For cell viability assays, MHCC97H
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cells were trypsinized and seeded at 1 × 104 cells/well in
a 96-well plate. After 24 h, various concentrations of
IVC were added, followed by incubation for another
48 h. Next, 10 μl CCK8 (Dojindo) solution was added to
each well and the plate was incubated for additional 2 h.
Absorbance readings at 490 nm were obtained using a
spectrophotometer (Thermo Varioskan).
Statistical analysis
The data were expressed as mean ± standard errors (S.E.)
and examined for their statistical significance of difference
with ANOVA and the Student’s t-test. P-values of less
than 0.05 were considered statistically significant.
Results
IVC inhibits the proliferation of human cancer cells
Uncontrolled proliferation and robust angiogenesis (i.e.
VM) contribute to the growth and metastasis of cancers.
Thus, CCK-8 assay was first used to determine the effect
of IVC on the proliferation of human cancer cells. The
chemical structure of IVC is shown in Fig. 1a. IVC
inhibited the proliferation of different cancer cells in a
dose-dependent manner (data not shown). As shown in
Fig. 1b, IVC inhibited the proliferation of MHCC97H
cells in a dose-dependent manner with an IC50 value
35.7 ± 4.7 μM. These cells had been shown to have cap-
acity of VM formation in our previous study [17]. We
next performed colonial survival assay under more strin-
gent conditions to further explore the inhibitory effect of
IVC on MHCC97H cell proliferation. The results
showed that the number of remaining survival colonies
in the IVC-treated groups at 15 and 30 μM was signifi-
cantly lower than that of the control group (*P < 0.05
and **P < 0.01; Fig. 1c and d). Together these results in-
dicate that IVC effectively inhibited MHCC97H cell pro-
liferation in vitro. We thus used MHCC97H cells as a
model to study the anti-VM potency and mechanism of
IVC in subsequent analyses.
IVC affects cell cycle progression of MHCC97H cells
To investigate the mechanism of the inhibitory effect of
IVC on MHCC97H cell growth, flow cytometry was per-
formed to analyze the cell cycle distribution after DNA
staining. IVC treatment at doses of 15, 30 and 60 μM sig-
nificantly increased the MHCC97H cell population at the
G1 phase (*P < 0.05 and **P < 0.01, vs. control; G0 phase
not shown, P > 0.05 vs. control; Fig. 2a and b). We next
performed real time-qPCR analyses of key cell cycle regu-
latory genes (primers are shown in Table 1). Real time-
qPCR results showed that the mRNA expressions of
Table 2 Sequences of primers
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Size
VE-cadherin CATTTGTCGTGCCTGAAGAC ATGGTGAAAGCGTCCTGGTA 133
EphA2 CCCGGAGGACGTTTACTTCT GGATGGATGGATCTCGGTAG 124
PI3K CGTTTCTGCTTTGGGACAAC CCTGATGATGGTCGTGGAG 100
MMP14 TATGGCTTCTGCCCTGAGAC GGGTTTCTTCTGCCCACTT 120
MMP2 TATGGCTTCTGCCCTGAGAC CACACCACATCTTTCCGTCA 142
MMP9 CAGTCCACCCTTGTGCTCTT ACTCTCCACGCATCTCTGC 118
LAMC2 ACATTCCTGCCTCAGACCAC TCCCTTGTCAGTTGCTCCAT 121
All the sequences are based on the published data on the National Center for Biotechnology Information followed by the accession number
Table 1 Sequences of primers
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Size
CDK-2 TACTTCTATGCCTGATTACA TGGGGTACTGGCTTGGTCAC 199
CDK-4 GCTACCAGATGGCACTTACACC GCAAAGATACAGCCAACACTCC 118
CDK-6 GCCCACTGAAACCATAAAGGA TACCACAGCGTGACGACCA 204
Cynlin-A1 TGTCACCGTTCCTCCTTGG GGGCATCTTCACGCTCTATTT 125
Cynlin-B1 GCTCTTGGGGACATTGGTAAC CAAAATAGGCTCAGGCGAAA 234
Cynlin-C1 TTGATTGCTGCTGCTACTTCTG CGTTCTGTAGGTATCATTCACT 237
Cynlin-D1 GGAACAGAAGTGCGAGGAGG GGATGGAGTTGTCGGTGTAGAT 191
Cynlin-E1 CCTGGATGTTGACTGCCTTGA TGTCGCACCACTGATACCCT 113
p21 GACACCACTGGAGGGTGACT CACATGGTCTTCCTCTGCTG 166
p27 TAGAGGGCAAGTACGAGTGG CAGGTCGCTTCCTTATTCC 258
P53 GTTCCGAGAGCTGAATGAGG TGAGTCAGGCCCTTCTGTCT 157
All the sequences are based on the published data on the National Center for Biotechnology Information followed by the accession number
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CDK-2 and cyclin-E1 were dramatically down-regulated
after treatment of cells with IVC (15, 30 and 60 μM), and
CDK-4 and cyclin-D1 were slightly decreased after IVC
treatment at doses of at least 60 μM, while p21 and p53
mRNA levels were markedly increased (*P < 0.05, **P <
0.01 and ***P < 0.001 vs. control; Fig. 2c). However, the ex-
pression levels of several other cell cycle regulators includ-
ing CDK-6, cyclin-B1 and p27 were not significantly
affected (P > 0.05 vs. control; Fig. 2c). Furthermore, west-
ern blot confirmed that the protein level of CDK-2 and
cyclin-E1 was markedly decreased after 30 and 60 μM
IVC treatment, while p21 and p53 protein expressions
were significantly upregulated after 15, 30 and 60 μM IVC
treatment (*P < 0.05, **P < 0.01 and ***P < 0.001 vs. con-
trol; Fig. 2d and e). Collectively, these results suggest that
IVC suppressed MHCC97H cell proliferation by inducing
cell cycle arrest at the G1 phase via decreasing the
expression of CDK-2 and cyclinE1 and enhancing the ex-
pression of p21 and p53 genes.
IVC induces apoptotic death of MHCC97H cells
To test whether IVC-mediated growth inhibition was
due to the induction of cell apoptosis, the Annexin V-PE
and 7-AAD assay was used to examine apoptosis in
MHCC97H cells treated with various concentrations of
IVC. As shown in Fig. 3a and b, the population of early
apoptotic (PE Annexin V+/7-AAD- events) MHCC97H
cells was increased significantly after highdose (>7.5 μM)
IVC treatment (*P < 0.05, **P < 0.01 and ***P < 0.001 vs.
control). Consistent with these results, poly (ADP-ri-
bose) polymerase (PARP), Caspase3 and Bcl-2 were
down-regulated after IVC treatment, while cleaved
Caspase3 and cleaved PARP were up-regulated (*P < 0.05
and **P < 0.01 vs. control; Fig. 3c and d). Together these
Fig. 1 Inhibitory effects of IVC on the proliferation of different human cancer cell lines. a Structure of IVC. b Various cancer cell lines were incubated
with IVC for 48 h, and cell growth was measured by CCK-8 assay. c and d Colony formation assay was performed after MHCC97H cells were treated
with IVC at indicated doses, and the number of colonies was manually counted. Original magnification was 40×, scale bars represent 500 μm
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results suggest that apoptotic cell death might contribute
to IVC-induced anti-proliferation effect in MHCC97H
cells.
IVC mediates biological effect via inhibition of ROCK
To investigate the effect of IVC on ROCK, MHCC97H cells
were treated with indicated doses of IVC and analyzed by
western blotting to evaluate phosphorylated levels of the
ROCK substrate MYPT1 (p-MYPT-1) and total level of
MYPT-1. Y27632 (ROCK inhibitor) was included as a posi-
tive control. Figure 4a shows that IVC treatment decreased
the level of p-MYPT-1 in a concentration-dependent man-
ner. Furthermore, IVC at 30 μM was more potent in de-
creasing p-MYPT-1 at all concentrations, which was similar
to the case with 50 μM Y27632 as shown in Fig. 4b.
Stress fiber formation is a cytoskeleton re-organization
process mediated by the activation of the Rho/ROCK
pathway. To determine the effects of IVC on these mor-
phological changes, MHCC97H cells were starved and
treated with IVC, Y27632 or vehicle, and then stained
with phalloidin as described in Methods. Figure 4c
shows that IVC dose-dependently inhibited stress fiber
formation, which is known to be critical to cell motility,
suggesting that this regulator may interfere with the abil-
ity of cancer cells to migrate and invade, or even VM.
IVC suppresses HCC cell motility
VM is believed to be associated with cell migration and in-
vasion. To explore the function of IVC in the migration
ability of MHCC97H cells, IVC (7.5, 15 and 30 μM) was
used in wound-healing and invasion assays, using Y27632
(50 μM) as positive control. In untreated MHCC97H cells,
cell migration toward the wounded area was observed and
cells were grown to near confluence within 24 h, while
Fig. 2 IVC affects cell cycle progression. a MHCC97H cells were incubated with IVC at indicated doses for 24 h, and the DNA content of
propidium iodide-stained cells was analyzed by flow cytometry. b Cell cycle distribution was analyzed. c mRNAs of cell cycle regulatory genes
were detected by real time-qPCR assay. d Protein expressions of CDK-2, cyclin-E1, p21, and p53 were detected by western blot. e The relative
protein level in each condition was quantitated using Image J and represented as a line chart corresponding to pixels detected. Data are
expressed as mean ± S.E. (n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the control
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addition of IVC (30 μM) to cells blocked their migration
within 48 h (P > 0.05 vs. 0 h; Fig. 5a and b). These results
indicate that cultured cells treated with IVC failed to
migrate. Knowing that the ability of cancer cells to
metastasize depends on their ability to invade, we
next investigated the ability of IVC to inhibit cell in-
vasion. Figure 5c showed that cell invasion decreased
by about 44 % and 73 % after incubation with 15 μM
and 30 μM IVC, respectively, compared with control
cells (**P < 0.01 and ***P < 0.001; Fig. 5d). No signifi-
cant difference in the wound-healing rate and inva-
sion activity was observed between positive control
cells and cells treated with IVC (30 μM). These re-
sults suggest that IVC inhibited cell motility and VM
formation in a dose-dependent manner.
IVC suppresses VM formation in MHCC97H cells
To detect whether IVC had an inhibitory effect on
MHCC97H cell-mediated neovascularization in vitro, we
observed the morphology of cell seizure activity in cul-
ture medium containing IVC, using Y27632 (50 μM) as
the positive control. MHCC97H cells were seeded onto
Matrigel, and the formation of VM structures was moni-
tored and photographed after 8 and 24 h (Fig. 6a).
MHCC97H cells without treatment gradually formed
characteristic tubular structures within 8 h and were com-
pleted within 24 h. IVC disrupted the formation of tubule-
like structures in a dose-dependent manner (**P < 0.01
and ***P < 0.001 vs. control; Fig. 6b). Compared with the
control, treatment with 30 μM IVC reduced VM forma-
tion by almost 85 %.
Fig. 3 IVC induces apoptotic death. a MHCC97H cells were incubated with IVC at indicated doses for 24 h, and Annexin V-PE and 7-AAD stained
cells were sorted by flow cytometry. b Distribution of cell apoptosis was analyzed. c Protein expressions of Caspase3, Cleaved Caspase3, PARP
and Bcl-2 were detected by western blot. d The relative protein level in each condition was quantitated using Image J. Experiments were
repeated three times, and similar results were obtained. Data are expressed as mean ± S.E. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the control
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To further examine the mechanism underlying the IVC-
mediated anti-VM effect, VM-associated genes, including
VE-cadherin, EphA2, PI3K, MMP-14, MMP-2, MMP-9
and LAMC2, were evaluated using real-time qPCR
(primers shown in Table 2). Similar to the 50 μM Y27632
positive control, mRNA levels were significantly down-
regulated by IVC (15 and 30 μM) compared with the
controls (*P < 0.05 and **P < 0.01; Fig. 6c). Furthermore,
immunofluorescence (Fig. 6d) and western blot analyses
(Fig. 6e and f) confirmed that VE-cadherin, PI3K, MMP-2
and MMP-9 proteins were down-regulated by IVC in
MHCC97H cells. These results demonstrate that IVC had
the potential to exogenously affect VM activity of
MHCC97H cells, and strongly imply that IVC may sup-
press VM development through the Rho/ROCK pathway.
Discussion
Gene-expression analysis of human HCC has led to the
successful molecular classification of HCC into six ro-
bust subgroups of cancers (G1–G6) associated with clin-
ical and genetic characteristics [21]. Despite the recent
advances in treatment, the mortality rate of HCC re-
mains high, and therefore new effective anti-HCC drugs
are urgently needed. Better understanding about the mo-
lecular mechanism of HCC invasiveness is essential for
the development of effective treatment of HCC. It is
generally recognized that the high metastatic ability of
HCC cells is the critical reason for the fatalities associ-
ated with HCC [22]. The growth and metastasis of HCC
cells depend on an effective microcirculation. Effective
microcirculation in aggressive tumors consists of vascu-
logenesis, angiogenesis and VM causing resistance to
conventional anti-angiogenic medicaments, and thus
many researchers have been seeking to develop new an-
giogenic and VM inhibitors from cleaved proteins,
monoclonal antibodies, synthesized small molecules and
natural products [23, 24]. These new anti-vascular thera-
peutic agents should be able to target both angiogenesis
and VM, anti-VM therapy for tumor VM [25]. Although
IVC was originally identified as a precursor compound
of incarvillateine, details about the pharmacological
mechanism underlying the anti-tumor activity of IVC
have not been clarified. The results of the present study
demonstrated that IVC exhibited remarkable inhibitory
effect on several types of cancer cells, including
MHCC97H cells. Importantly, IVC dose-dependently
inhibited the proliferation of MHCC97H cells, which
are known to have the capacity of VM formation
[17], suggesting that IVC is a potential new anti-HCC
drug candidate.
Deregulation of the cell cycle leads to robust tumor
cell proliferation, which is an important hallmark of can-
cer [26]. Progression through the S-phase must be
strictly controlled so that cells undergo only a single
round of chromosomal DNA replication. Our cell cycle
analyses demonstrated that IVC caused the accumula-
tion of MHCC97H cells at G1 phase and only CDK-2
and cyclin-E1 were down-regulated after IVC treatment.
Previous studies reported that the CDK-2/cyclin-E1
complex plays a crucial role during the transition from
G1- into S-phase [27]. CDK inhibitors including p21 and
p27 and the tumor suppressor p53 also play a key role
in regulating cell cycle progression through suppressing
Fig. 4 IVC as a mediator of ROCK. a MHCC97H cells were treated
with increasing concentrations of IVC for 24 h and p-MYPT-1 was
examined by western blot. ROCK inhibitor Y27632 was used as the
positive control. b The relative protein level in each condition was
quantitated using Image J. c IVC inhibits the formation of stress
fibers. Starved MHCC97H cells were treated with either vehicle,
Y27632 or IVC for 1 h and then fixed and stained with phalloidin
(green) and DAPI (blue). Original magnification was 400×, scale bars
represent 25 μm. Data are representative of three independent
experiments. Data are expressed as mean ± S.E. *P < 0.05 and
**P < 0.01 vs. the control
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CDK-2 activity and G1/S phase transition [28, 29]. Our
real time-qPCR and western blot results showed that
p21 and p53 were up-regulated after IVC treatment,
without any changes on the other CDKs/cyclins, sug-
gesting that IVC induced MHCC97H cell cycle arrest at
G1 phase probably via upregulating p21 and p53. We
also found that 15 μM IVC treatment induced significant
cell apoptosis, and this IVC-induced apoptosis may be
associated with PARP and Caspase3 degradation, which
is consistent with other studies [30]. These results sug-
gest that IVC may be a potential antiproliferation agent
for HCC.
Accumulating evidence indicates that Rho and the
downstream target ROCK plays an important role in
oncogenesis. ROCK promotes actin filament stabilization
and the generation of actin-myosin contractility. Y27632
or fasudil, inhibitors of ROCK, caused loss of actin stress
fibers and focal adhesion complexes [31]. We found that
treatment of MHCC97H cells with IVC decreased the
level of p-MYPT-1 and distributed stress fiber formation
in a concentration-dependent manner similar to the case
with Y27632 (Fig. 4), indicating that IVC is a potential
mediator of Rho/ROCK. Given the volume of the litera-
ture supporting a role for Rho/ROCK in controlling cell
movement, it is not surprising to find that inhibition of
IVC blocked MHCC97H migration and invasion, which
is similar to the finding of our previous study [17]. The
inhibitory effects of IVC with different concentrations
on cell migration and invasion and ROCK activity were
below IC50 value of 35.7 ± 4.7 μM in order to avoid po-
tential toxicity. Thus, IVC could effectively exert a regu-
lated impact on cell migration and invasion, but are
hardly associated with cytotoxicity of the compound.
Rho GTPases contribute to multiple cellular processes
that could affect cancer progression, including cytoskeletal
dynamics, transcriptional regulation, vesicle trafficking,
Fig. 5 Inhibitory effect of IVC on MHCC97H cell motility. a Cells were plated, incubated for 8 h, scratched and treated with vehicle, IVC or Y27632.
Representative images of scratch wounds formed at 0, 24 and 48 h after wounding. Original magnification was 100×, scale bars represent
125 μm. c MHCC97H cells were treated with vehicle, IVC or Y27632, plated in Corning Transwell inserts coated with Matrigel, and allowed to
invade for 48 h. Original magnification was 200×, scale bars represent 75 μm. b and d Data were normalized to untreated cells and the relative
migration or invasion is expressed as mean ± S.E. of triplicate experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the control
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apoptosis, cell cycle progression and migration [32].
ROCK activity is necessary for progression from G1 to S-
phase by controlling the expression of cyclins, CDKs, and
numerous other cell cycle regulators [33]. Furthermore,
ROCK activity has been shown to promote CDK-2 and
cyclin-E1 translocation into the nucleus [34], suggesting
that inhibition of ROCK signaling may lead to cell cycle
arrest in G1 phase. Moreover, ROCK inhibition has been
shown to increase phosphorylation of p53 [35, 36].
Additionally, ROCK proteins are essential for multiple
Fig. 6 The impact of IVC on VM formation. a VM formation of MHCC97H cells cultured in a Matrigel-coated 24-well plate with culture medium
containing IVC (7.5, 15 or 30 μM) or Y27632 (50 μm) for 8 h or 24 h. Photographs were taken at the indicated time points. Original magnification was
100×, scale bars represent 125 μm. b Quantitative analysis of the mean number of tube-like structures formed from six randomly chosen areas in 3D
cultures. c Real-time qPCR analysis was used to determine changes in gene expression. Relative IVC-induced change in gene expression compared
with GAPDH is expressed as fold change calculated by 2-ΔΔCp method. Y27632 (50 μM) was used as positive control. d Representative confocal images
(n = 3, five pictures per condition) of control and IVC (7.5, 15 or 30 μM) with 24 h incubation after immunostaining for VE-cadherin, PI3K, MMP-2 or
MMP-9 (green) and DAPI (blue). Scale bars represent 50 μm. e Western blot assay was performed to evaluate the effect of IVC or Y27632 on VM
markers, using GAPDH as an internal control for protein loading. f Relative protein level was quantitated using Image J. Data are expressed as
mean ± S.E. from three independent experiments, with significant differences from control designated as *P< 0.05, **P < 0.01 and ***P< 0.001
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aspects of both the intrinsic and extrinsic apoptotic pro-
cesses, including regulation of cytoskeletal-mediated cell
contraction and membrane blebbing, nuclear membrane
disintegration, modulation of Bcl-2 family member and cas-
pase expression/activation and phagocytosis of fragmented
apoptotic bodies [34]. This finding could serve as an ex-
planation why IVC not only mediates G1 arrest but also in-
duces apoptosis. Together our results suggest that IVC
mediates the proliferation of human cancer cells via down-
regulating the Rho/ROCK pathway.
However, our previous finding that ROCK inhibitor:
Y27632 at the concentrations up to 50 μM does not es-
sential for survival and proliferation of MHCC97H cells
[17], which is different to the results of IVC, suggests
Y27632 and IVC have distinct effects on cell prolifera-
tion and apoptosis. In respect of these differences, we
found that long-term treatment with fasudil improved
pulmonary vascular remodeling with suppression of vas-
cular smooth muscle cells (VSMC) proliferation and en-
hancing of VSMC apoptosis [37], which is similar to the
result of IVC but is different to Y27632 [17], indicating
that each compound has various functions with respect-
ive or unique mechanism. Interestingly, Y27632 has been
reported to have opposite effects on cell motility. Koga
et al. [38] reported that Y27632 promoted human tra-
becular meshwork cells in adhesion, contraction and
motility, which was inconsistent with our or other re-
ports [17, 39, 40], implying that same compound has a
wide variety of effects on different cell line. Moreover,
growing number of ROCK inhibitors have been re-
ported, however, their pharmacological effects varied in
different diseases [41].
Besides, it is well known that ROCK have two subtypes:
ROCK1 and ROCK2. However, Y27632 targets the highly
conserved kinase domain of ROCK, which does not dis-
tinguish between ROCK1 and ROCK2 isoforms. Inhib-
ition of ROCK1 resulted in a decreased proliferation,
whereas inhibition of ROCK2 had the opposite effect, sig-
nificantly enhancing proliferation relative to the control
cells and regulating cyclin D1 [42–44] to mediate the ca-
nonical Wnt/TCF pathways involving β-catenin. There-
fore, the relative contribution of these kinases to the
effects of Y27632 treatment differ in different cell types
and cellular processes. This is an important consideration
in developing specific therapeutics tailored to distinct cel-
lular responses and diseases. Taken together, our manu-
script showed that Y27632 and IVC have distinct effects
on cell proliferation and apoptosis, further investigation
will be performed to explain what’s different.
Our previous study reported that selective blockage of
ROCK with Y27632 reduced the formation of tubule-like
structures in a dose-dependent manner [17]. Therefore,
we further investigated the anti-VM activity of IVC. Simi-
larly, here we found that IVC reduced VM in a dose-
dependent manner compared with Y27632. The key
signaling pathway of VM formation is the colocalization
of VE-cadherin and activation of PI3K by EphA2, which
subsequently induce the expression and activation of
MMP-14, which subsequently triggers MMP-2 activation.
MMP-14 and MMP-2 promote the cleavage of LAMC2 to
the pro-migratory γ2′ and γ2 × fragments. Our investigation
showed that VM-associated genes were down-regulated,
suggesting that IVC could attenuate the characteristics asso-
ciated with tumor cell plasticity essential for VM. To prove
IVC as a potential anti-VM candidate, we will continue to
perform animal experiments to examine tumor size,
invasion and VM-associated genes in nude mice.
Conclusions
Our data presented here demonstrate that IVC, as a me-
diator of ROCK, possesses anti-HCC ability by inducing
cell cycle arrest and cell apoptosis as well as suppressing
tumor cell migration and VM in vitro. Thus, IVC may
be a potential anti-VM candidate for anti-HCC therapy.
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